[go: up one dir, main page]

MA26965A1 - Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase. - Google Patents

Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.

Info

Publication number
MA26965A1
MA26965A1 MA27166A MA27166A MA26965A1 MA 26965 A1 MA26965 A1 MA 26965A1 MA 27166 A MA27166 A MA 27166A MA 27166 A MA27166 A MA 27166A MA 26965 A1 MA26965 A1 MA 26965A1
Authority
MA
Morocco
Prior art keywords
diabetic
prodrug
combinations
reductase inhibitors
gaba
Prior art date
Application number
MA27166A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26965A1 publication Critical patent/MA26965A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 30 Novembre 2000 60/250,448 Voir en annexe le titre de l„invention et le texte de l„abrégé Association d'agonistes de GABA et d'inhibiteurs d'aldose-réductase L'invention concerne des compositions pharmaceutiques comprenant des associations d'un agoniste de GABA, d'un de ses précurseurs médicamenteux ou d'un sel pharmaceutiquement acceptable dudit agoniste de GABA ou dudit précurseur médicamenteux, et d'un ARI, d'un de ses précurseurs médicamenteux ou d'un sel pharmaceutiquement acceptable dudit ARI ou dudit précurseur médicamenteux, des kits contenant ces associations, et des méthodes d'utilisation de ces associations pour le traitement de mammifères, y compris l'homme, souffrant de complications diabétiques telles que la neuropathie diabétique, la néphropathie diabétique, la myocardiopathie diabétique, la rétinopathie diabétique, la microangiopathie diabétique, la macroangiopathie diabétique, les cataractes ou les ulcères des pieds.
MA27166A 2000-11-30 2003-05-20 Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase. MA26965A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25044800P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
MA26965A1 true MA26965A1 (fr) 2004-12-20

Family

ID=22947799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27166A MA26965A1 (fr) 2000-11-30 2003-05-20 Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.

Country Status (34)

Country Link
US (1) US6720348B2 (fr)
EP (1) EP1337272A2 (fr)
JP (1) JP2004514700A (fr)
KR (1) KR20030059287A (fr)
CN (1) CN1477976A (fr)
AP (1) AP2001002359A0 (fr)
AR (1) AR031432A1 (fr)
AU (1) AU2002215160A1 (fr)
BG (1) BG107812A (fr)
BR (1) BR0115776A (fr)
CA (1) CA2430309A1 (fr)
CR (1) CR6962A (fr)
CZ (1) CZ20031387A3 (fr)
DO (1) DOP2001000294A (fr)
EA (1) EA200300433A1 (fr)
EC (1) ECSP034629A (fr)
EE (1) EE200300249A (fr)
HR (1) HRP20030419A2 (fr)
HU (1) HUP0302555A3 (fr)
IL (1) IL155710A0 (fr)
IS (1) IS6787A (fr)
MA (1) MA26965A1 (fr)
MX (1) MXPA03004871A (fr)
NO (1) NO20032387D0 (fr)
OA (1) OA12413A (fr)
PA (1) PA8534201A1 (fr)
PE (1) PE20020598A1 (fr)
PL (1) PL365378A1 (fr)
SK (1) SK6092003A3 (fr)
SV (1) SV2003000752A (fr)
TN (1) TNSN01170A1 (fr)
UY (1) UY27044A1 (fr)
WO (1) WO2002043763A2 (fr)
ZA (1) ZA200303340B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
AU2003243603A1 (en) * 2002-06-13 2003-12-31 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2314289A1 (fr) * 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
JP2009533368A (ja) 2006-04-11 2009-09-17 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2008077597A1 (fr) * 2006-12-22 2008-07-03 Novartis Ag Dérives de 1-aminométhyl- l- phényl- cyclohexane comme inhibiteurs de ddp-iv
US8273746B2 (en) 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
EP2116618A1 (fr) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnostic et traitement de la maladie de Kawasaki
EP2309858A4 (fr) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd Compositions et procédés de traitement de troubles inflammatoires
PL2326632T3 (pl) * 2008-09-06 2017-10-31 Bionevia Pharmaceuticals Inc Nowy kokryształ choliny i epalrestatu
WO2012088525A2 (fr) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Méthodes de traitement de copd
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN107847548B (zh) * 2015-05-18 2022-06-14 贝思以色列女会吏医学中心公司 P物质、肥大细胞脱颗粒抑制剂和周围神经病
JP7171611B2 (ja) * 2017-04-21 2022-11-15 スティーブン・ホフマン 網膜症を治療するための組成物及び方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12433904B2 (en) 2019-04-17 2025-10-07 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
CN116235853B (zh) * 2022-12-28 2025-11-04 中国农业大学 一种植物生长调节剂及其在促进植物生长、提高植物产量和增强植物抗逆性中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
US4130714A (en) 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS5625169A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4791126A (en) 1980-08-22 1988-12-13 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
CA1176269A (fr) 1981-03-02 1984-10-16 Kazimir Sestanj Derives de n-naphtoylglycine
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5066659A (en) 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
AU602641B2 (en) 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use
EP0264586B1 (fr) 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Dérivés de l'hydantoine pour le traîtement de complications du diabète
US4771052A (en) * 1987-02-05 1988-09-13 Hoechst-Roussel Pharmaceuticals, Inc. Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines and their use as hypotensive agents
GB8801037D0 (en) 1988-01-18 1988-02-17 Plessey Co Ltd Improvements relating to fuel supply systems
US5252572A (en) * 1988-02-03 1993-10-12 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4980357A (en) 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5037831A (en) 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
ATE264311T1 (de) * 1999-04-01 2004-04-15 Pfizer Prod Inc Verbindungen zur behandlung und vorsorge bei diabetes
AU782344C (en) * 1999-04-08 2006-08-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders

Also Published As

Publication number Publication date
JP2004514700A (ja) 2004-05-20
HUP0302555A2 (hu) 2003-11-28
HUP0302555A3 (en) 2005-06-28
WO2002043763A3 (fr) 2003-03-13
UY27044A1 (es) 2002-07-31
OA12413A (en) 2004-09-30
US20020077319A1 (en) 2002-06-20
TNSN01170A1 (fr) 2005-11-10
BR0115776A (pt) 2004-01-13
SV2003000752A (es) 2003-01-13
KR20030059287A (ko) 2003-07-07
CZ20031387A3 (cs) 2004-04-14
AP2001002359A0 (en) 2001-12-31
PA8534201A1 (es) 2002-10-24
PL365378A1 (en) 2005-01-10
BG107812A (bg) 2004-02-27
NO20032387L (no) 2003-05-27
AR031432A1 (es) 2003-09-24
HRP20030419A2 (en) 2004-08-31
US6720348B2 (en) 2004-04-13
ECSP034629A (es) 2003-07-25
ZA200303340B (en) 2004-04-30
CA2430309A1 (fr) 2002-06-06
AU2002215160A1 (en) 2002-06-11
EE200300249A (et) 2003-10-15
CN1477976A (zh) 2004-02-25
EP1337272A2 (fr) 2003-08-27
DOP2001000294A (es) 2002-08-30
WO2002043763A2 (fr) 2002-06-06
CR6962A (es) 2004-02-02
NO20032387D0 (no) 2003-05-27
IL155710A0 (en) 2003-11-23
MXPA03004871A (es) 2003-08-19
EA200300433A1 (ru) 2003-10-30
IS6787A (is) 2003-04-14
SK6092003A3 (en) 2004-07-07
PE20020598A1 (es) 2002-07-08

Similar Documents

Publication Publication Date Title
MA26965A1 (fr) Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA30604B1 (fr) Agonistes de ep2
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA30602B1 (fr) Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs
MA30652B1 (fr) Composes organiques
MA30412B1 (fr) Composés Pharmaceutiques
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA27003A1 (fr) Pyridazinones servant d'inhibiteurs d'aldose-reductase.
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles